We’ll help you find the highest quality medicine that you need.
is a treatment indicated for:
1) First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
2) Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
3) Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
4) First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Manufactured by: Genentech
Active Ingredient(s): Erlotinib Hydrochloride
Dosage Form: Tablet, oral
Strength: 25 mg, 100 mg, 150 mg
FDA approved: November 18, 2004
More information about Tarceva:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s026lbl.pdf
is indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included Imatinib.
Manufactured by: Novartis
Active Ingredient(s): Nilotinib Hydrochloride Monohydrate
Dosage Form: Capsule, oral
Strength: 150 mg, 200 mg
FDA approved: October 29, 2007
More information about Tasigna:
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=022068